Huma
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
Huma firmographics
Firmographics- Name
- Huma
- Legal name
- Huma Therapeutics Limited
- Website
- https://huma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Huma industry classification
Industry- Product category
- Healthcare SaaS / Digital Health Platform
- NAICS
- Software Publishers (5132), Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000)
- akta.pro primary industry
- Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management) (HLALAFAL)
- akta.pro secondary industries
- Remote Patient Monitoring (RPM) Platforms & Services (HLACAPAA), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), AI/Analytics for RPM (Risk Stratification, Alerts, Predictive) (HLACAFAM), RPM Reimbursement, Billing & Program Operations Platforms (HLACAFAN), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)
Keywords
Where Huma is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Huma business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing (SaaS): Huma Cloud Platform is offered as a licensed infrastructure to healthcare organizations, pharmaceutical companies, and digital health startups enabling rapid deployment of regulated digital health solutions. The platform's regulatory certifications (FDA Class II, EU MDR IIb, etc.) allow customers to launch compliant products faster.
- Remote Patient Monitoring (RPM) Reimbursement: Huma's RPM products generate revenue through Medicare/Medicaid reimbursement codes in the US market. The respiratory RPM product covers 140,000 contracted lives with growing reimbursement streams.
- Pharmaceutical Partnerships: Revenue from partnerships with pharmaceutical companies for companion apps, clinical trial platforms, and disease management solutions. Collaborations with Bayer, UCB, Merck KGaA, Pfizer, AstraZeneca, and others.
- Clinical Research Services: End-to-end digital clinical trial solutions combining Huma's technology platform with Alcedis' 25+ years of clinical and operational expertise. Manages nearly 1000 studies across 60+ countries.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Huma product offering
Product offeringCore offering
Huma provides a regulated, disease-agnostic Software as a Medical Device (SaMD) platform — the Huma Cloud Platform — that unifies clinical, operational, and research data and enables no-code configuration of digital health applications. The company sells platform licensing, AI-powered clinical intelligence tools, remote patient monitoring modules, companion apps for pharmaceutical partners, and end-to-end digital clinical trial services to healthcare systems, pharmaceutical companies, and government health agencies across 70+ countries.
Product overview
Huma offers a modular platform architecture centered on the Huma Cloud Platform—a disease-agnostic, regulated Software as a Medical Device (SaMD) that unifies clinical, operational, and research data. The platform enables no-code configuration of regulated disease management tools and hosts AI/ML algorithms. The product portfolio spans Platform Tools (Huma Workspace for low-code app building, Huma Intelligence for AI analytics and agents, Huma Intelligence Scribe for clinical transcription), Primary Care solutions (eConsult for AI-first triage, myGP for patient access), Secondary Care (A&E eTriage for emergency departments, GDm Health for gestational diabetes, Huma MG for Myasthenia Gravis, Respiratory/Aluna for lung monitoring), Public Health (iplato for population engagement, CVD AI Screening for cardiovascular prevention), and Clinical Trials (Alcedis-powered platform for decentralized and hybrid trials). The platform integrates pre-built modules, device connectivity, and supports partnerships like Bayer's Heart Health Risk Assessment.
Differentiator
Problem solved
Functional benefit
Brands
- eConsult: AI-First Primary Care — a unified consultation platform for faster, safer triage, collecting structured clinical information and routing patients efficiently for primary and emergency care.
- Huma myGP
- Alcedis
- Aluna
- A&E eTriage
- GDm Health
- Huma MG
- iPlato
- CVD AI Screening
- Huma Intelligence Scribe
Products and services
- Huma Cloud Platform A governed, disease-agnostic cloud platform that unifies clinical, operational, and research data. Enables rapid, no-code configuration of regulated disease management tools with pre-built modules, device connectivity, AI/ML algorithm hosting, and a marketplace for digital health applications. Sold to healthcare systems, pharmaceutical companies, government health agencies, and digital health startups.
- Huma Intelligence Scribe AI-powered transcription of clinical consultations that turns real-time dialogue into structured, usable data. Built on NVIDIA AI technology, it forms structured, usable data making regulated AI workflows easier to deploy at scale. Deployed at scale across the United States.
- Huma Intelligence (Hi) A full suite of AI-powered capabilities including analytics, AI agents, and ML tools that turn connected data into action. Serves healthcare organizations, governments, and life science partners with clinical-grade intelligence for patient monitoring, risk prediction, and decision support.
- Huma Workspace Low-code platform tools for building and operating care workflows, data, and AI applications. Allows regulated AI health apps to be built faster, safer, and with less effort using drag-and-drop functionality.
- eConsult (AI-First Primary Care) A unified consultation platform for faster, safer triage in primary care. Collects structured clinical information, routes patients efficiently, and frees clinician time with smart inbox tools and automated workflows. Used by NHS primary care and supports 50M+ consultations.
- Huma myGP The UK's #1 medical app for everyday healthcare access. Empowers millions with seamless access to appointments, prescriptions, health records, and an expanding ecosystem of wellness services. Used by 31 million people across the UK.
- A&E eTriage Digital triage system designed for Emergency and Urgent Care settings. Speeds assessments, prioritizes patients accurately, and supports clinicians with tools developed in partnership with frontline NHS teams.
- GDm Health The #1 digital program for diabetes in pregnancy. Helps clinicians manage gestational diabetes through real-time monitoring, structured data, and proven clinical outcomes.
- Huma MG A medical-grade app and remote monitoring platform for Myasthenia Gravis. Tracks symptoms, monitors trends, and supports personalized treatment with assessments and enhanced patient-clinician communication tools.
- Aluna (Respiratory Monitoring) Real-time lung health monitoring with hospital-grade accuracy. Measures lung function and shares actionable insights across asthma, cystic fibrosis, and respiratory monitoring.
- iplato (Population Health Engagement) Digital engagement tools that transform patient pathways. Improves activation, communication, and access across primary care with population-level health tools and integrated engagement solutions.
- CVD AI Screening Smarter cardiovascular care at population scale. Supports prevention programs with Heart Health Screening at scale, AI advanced analytics, and streamlined workflows designed for measurable outcomes.
- Alcedis (Clinical Trials Platform) Digital-first clinical research platform for modern trials. Integrates decades of research expertise with digital workflows, AI-powered tools, and end-to-end services for smarter, compliant studies across all phases. Manages nearly 1000 studies across 60+ countries.
- Bayer Aspirin Heart Health Risk Assessment Digital-only cardiovascular risk assessment tool that rapidly evaluates an individual's risk for developing CVD over the next decade without invasive blood tests. Uses algorithm leveraging 15+ years of longitudinal data from UK Biobank. Deployed via Bayer Aspirin consumer health brand.
Quantifiable outcome
- 90-95% patient adherence and retention across care and research applications
- +7 more outcomes
Companies that use Huma
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles5 records
Huma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature8 records
Huma partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and minor.
- Fresenius Medical CarecoreFresenius Medical Care launched kinexus, a unified digital platform for home dialysis, built on Huma Cloud Platform. Platform combines peritoneal dialysis and home hemodialysis management, enabling remote therapy monitoring and prescription management globally.
- Fresenius Medical Care (ERA Congress)coreFresenius previewed kinexus digital platform for home dialysis at European Renal Association Congress 2026. Platform developed in partnership with Huma with Fresenius Medical Care Deutschland as authorized distributor.
- NVIDIAcoreHuma Intelligence Scribe powered by NVIDIA AI technology. Huma launched AI-powered clinical consultation transcription built on NVIDIA infrastructure, forming structured data for regulated workflows deployed at scale in the U.S.
- Bayer (MENA Region)coreBayer's Consumer Health division partnership with Huma for cardiovascular risk assessment tool in MENA region. Bayer has engaged over 2 million people and trained 3,000+ healthcare providers in Egypt and Saudi Arabia for cardiovascular awareness.
- WheelcorePartnership to deliver Direct-to-Consumer Platform as a Service. Wheel integrates Huma Intelligence Scribe into its Horizon platform for AI-powered clinical documentation in virtual care settings across the U.S.
- Aluna (Acquisition)coreHuma acquired Aluna, a US-based respiratory monitoring company. Acquisition expands Huma's digital health ecosystem and respiratory health capabilities, integrating Aluna's respiratory monitoring solutions into Huma's cloud platform.
- PfizercoreHuma and Pfizer collaboration to launch Huma Cloud Platform for Hemophilia management. Digital solution to support hemophilia patients through treatment and care pathways.
- SamsungminorSamsung, Huma, and Tulane University partnership for the HEARTBEAT 10,000 Study, enrolling first patient in January 2025. Study integrates Samsung Galaxy Watch biometrics with Huma's platform for cardiovascular research.
- Eczacibasi Evital (Turkey)minorStrategic partnership bringing Huma's digital health solutions to Turkey. Evital is a health ecosystem with 1,000+ doctors and 3,000+ health professionals serving 30,000+ individuals. Huma provides access to Huma Cloud Platform including RPM, companion apps, and AI capabilities.
- Huma Cloud Platform LaunchcoreHuma launched its Cloud Platform in July 2024 enabling rapid, no-code creation and deployment of AI-powered regulated health applications. Platform features pre-built modules, device connectivity, and marketplace for third-party development.
- Bayer Consumer HealthcoreBayer and Huma partnership expanded to launch the Aspirin Heart Health Risk Assessment in Saudi Arabia, aligned with Vision 2030. Huma developed the algorithm using 15+ years of UK Biobank data. Bayer committed to screening 1,000,000 citizens in the 'Protect Your Heart' campaign.
- Merck KGaA, Darmstadt, Germany - Bladder CancercoreLaunched bladder cancer treatment companion app in UK. Developed in collaboration with healthcare professionals and patient organizations including World Bladder Cancer Patient Coalition. App provides treatment information, self-tracking, and care team communication.
- eConsult (Acquisition)coreHuma acquired eConsult, a UK digital triage and consultation platform provider for primary and emergency care. Acquisition follows Huma's earlier purchase of iPlato and aims to expand digital health solutions across UK healthcare landscape supporting 50M+ consultations and 80+ NHS Trusts.
- iPlato (Acquisition)coreHuma acquired iPlato Healthcare, a UK digital health company whose digital service is used by 31 million people across the UK. Part of Huma's primary care division driving recruitment into UK's largest research programme Our Future Health.
- Merck KGaA, Darmstadt, GermanycorePartnership to develop digital solutions for cancer patients. Initial launch for urothelial carcinoma patients in UK, with plans to support a range of cancers. Utilizing Huma's EU MDR Class IIb and FDA Class II cleared platform for cross-indication disease management.
- Google CloudcoreHuma uses Google Cloud's Vertex AI platform and explores Med-PaLM 2 for generative AI applications in healthcare. Collaboration aims to safely integrate generative AI into Huma's regulated disease management platform for clinical decision support, documentation automation, and patient engagement.
- UCBcorePartnership to provide digital health solution for Myasthenia Gravis (MG) rare disease management. Platform founded on Huma's EU MDR Class IIb regulated SaMD technology. Enables patients to track MG symptoms using MG-ADL scale with data shared to clinicians for early intervention.
- Alcedis GmbH (Acquisition)coreHuma acquired Alcedis GmbH, a German clinical research and technology provider with 25+ years of experience. Acquisition created advanced clinical trials division offering digital solutions across entire development pipeline. Alcedis manages nearly 1000 studies across 60+ countries.
- Bayer (Germany)coreBayer and Huma digital heart risk assessment tool. Featured in IMD business school case study on digital healthcare transformation alongside Merck Healthcare, CVS Health, Sanofi, Roche, Philips, and Novo Nordisk.
Scale indicators16 records
Huma competitors and assessment
Company assessmentDirect peers
- Biofourmis: Biofourmis is a regulated digital health platform combining RPM, AI predictive analytics, and care orchestration for hospital-at-home and chronic disease management. It is a direct competitor to Huma in the disease-agnostic, AI-enabled RPM platform category serving providers and pharma.
- Vivify Health: Vivify Health provides a connected health platform for remote patient monitoring and chronic care management, with multi-device connectivity and care pathways. It competes directly with Huma in the RPM and chronic condition management space serving providers and payers.
- Validic: Validic offers a healthcare data connectivity platform that streams personal health data from RPM devices into clinical systems. It is comparable to Huma in the medical-grade device connectivity and data integration layer of the RPM stack.
- Current Health (Best Buy Health): Current Health provides an FDA-cleared RPM platform with wearable monitoring and care coordination, acquired by Best Buy Health. It competes directly with Huma in continuous RPM for hospital-at-home and post-acute care use cases.
- WellDoc: WellDoc is a digital health company offering FDA-cleared chronic disease management platforms (notably diabetes) with companion apps and clinical decision support. It is comparable to Huma in regulated, condition-specific digital therapeutics with pharma partnerships.
- Omada Health: Omada Health is a virtual-first chronic care provider for diabetes, hypertension, and musculoskeletal conditions. While more payer-led than Huma, it competes in the digital chronic condition management space with strong outcomes evidence.
- Babylon Health: Babylon Health is a UK-founded digital health company offering AI-driven triage, virtual consultations, and population health tools. It overlaps with Huma's eConsult and primary care triage products in the UK and selected international markets.
Emerging players
- Doccla: Doccla is a UK-based virtual ward and RPM provider offering continuous monitoring and clinical oversight as a managed service to NHS Trusts. It is an emerging competitor to Huma's virtual ward and RPM deployments within the NHS specifically.
Broad incumbents
- Teladoc Health (Livongo): Teladoc Health is a broad telehealth and chronic condition management incumbent (via Livongo). It overlaps with Huma in virtual care, RPM, and chronic disease management but operates a much wider portfolio of services across many geographies.
- GE HealthCare: GE HealthCare is a large incumbent offering medical imaging, patient monitoring, and digital health infrastructure to hospitals. It overlaps with Huma in hospital-grade patient monitoring and care command centers, though from a hardware-anchored incumbent position.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Huma social profiles
Digital presenceHuma compliance and trust
Trust signalCompliance7 records
Huma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Huma leadership team
Management profileNumber of profiles
Profiles17 records
Huma subsidiaries and ownership
Company hierarchySubsidiaries4 records
Huma funding detail
Funding detailFunding overview
Funding rounds11 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Huma M&A and investment
M&A and investmentM&A7 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Huma
What does Huma do?
Huma provides a regulated, disease-agnostic Software as a Medical Device (SaMD) platform — the Huma Cloud Platform — that unifies clinical, operational, and research data and enables no-code configuration of digital health applications. The company sells platform licensing, AI-powered clinical intelligence tools, remote patient monitoring modules, companion apps for pharmaceutical partners, and end-to-end digital clinical trial services to healthcare systems, pharmaceutical companies, and government health agencies across 70+ countries.
Is Huma a public or private company?
Huma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Huma founded?
Huma was founded in 2011. It employs 501 to 1,000 people.
Where is Huma based?
Huma is headquartered in London, United Kingdom, in the Europe region.
How does Huma make money?
Four revenue lines are on record. Platform Licensing (SaaS) is the primary driver. The others are remote Patient Monitoring (RPM) Reimbursement, pharmaceutical Partnerships and clinical Research Services.
Who are Huma's main competitors?
Direct peers on record are Biofourmis, Vivify Health, Validic, Current Health (Best Buy Health), WellDoc, Omada Health and Babylon Health. Doccla is listed as an emerging player. Broad incumbents are Teladoc Health (Livongo) and GE HealthCare.
Does Huma have an API?
Yes. The Huma Cloud Platform offers readily available APIs and integration capabilities, cloud-agnostic framework for flexible hosting, and a Software Development Kit (SDK) to enable accelerated development of similar applications or to embed functionalities into existing solutions. Specific API documentation URL, authentication methods, and rate limits are not specified in the available sources.
What industry is Huma in?
Huma's product category is Healthcare SaaS / Digital Health Platform. Its primary akta.pro industry code is HLALAFAL, Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management), with a secondary code of HLACAPAA, Remote Patient Monitoring (RPM) Platforms & Services. Its NAICS code is 5132 and its SIC code is 7372.